Galapagos Genomics and Euroscreen sign GPCR deal

12 December 2001

Galapagos Genomics and fellow Belgian company Euroscreen have enteredinto a collaboration to identify activators of G-protein coupled receptors for which no ligands are known. The alliance, for which no financial details have been disclosed, will combine the former's PhenoSelect expression platform with Euroscreen's AequoScreen cell-based assay technology.

Under the terms of the agreement, Galapagos will supply Euroscreen with an arrayed collection of secreted proteins and peptides from human cells infected with its PhenoSelect library, that includes tens of thousands of human genes, which will be screened for ligands that activate orphan GPCRs. The companies said that this approach is unique in that the ligands identified in the screen can be immediately traced back to the corresponding gene in the PhenoSelect library, "significantly facilitating the further characterization of the ligand." The firms then plan to out-license the validated ligands to pharmaceutical and biotechnology companies for drug discovery programs.

Euroscreen's vice president of R&D, Richard White, said that GPCRs mediate about 90% of the signal transduction through the cell membrane "and are therefore very attractive drug targets for the pharmaceutical industry." He claimed that GPCRs are the target for about one-third of the leading 100 pharmaceutical products, naming such drugs as Schering-Plough's Claritin (loratadine), Merck & Co's Cozaar (losartan), Eli Lilly's Prozac (fluoxetine) and GlaxoSmithKline's Zantac (ranitidine) and Imitrex (sumatriptan).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight